DiaMedica Therapeutics Inc.

NASDAQ•DMAC

CEO: Mr. Dietrich John Pauls MBA

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2012-08-03

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Contact Information

301 Carlson Parkway, Suite 210, Minneapolis, MN, 55305, United States

(763)-496-5454

www.diamedica.com

Market Cap

$414.02M

P/E (TTM)

-12.4

17.5

Dividend Yield

52W High

$10.42

52W Low

$3.19

52W Range

66%

Rank62Top 92.6%

1.9

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.9 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.17+13.33%

4-Quarter Trend

FCF

-$6.62M+47.82%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Cash Position Strengthened Combined cash, equivalents, and securities total $55.3M as of September 30, 2025, up from $44.1M year-end 2024.

July Private Placement Closed Raised $30.0M net proceeds in July 2025 private placement, funding operations and clinical expansion efforts.

PE Trial Interim Results Investigator-sponsored PE Phase 2 Part 1a showed DM199 safe, well-tolerated with sustained blood pressure reduction.

Risk Factors

Operating Cash Burn Widens Net cash used in operating activities increased to $(21.3)M for nine months 2025 versus $(15.6)M prior year.

AIS Trial Enrollment Slow ReMEDy2 trial faces slower site activations and enrollment due to staffing shortages and protocol complexity.

Significant Future Capital Needed Expect substantial additional capital required to complete required clinical studies and achieve commercialization milestones.

Outlook

Key Clinical Milestones Targeted Planning FPI for PE Part 1b in 1H 2026; anticipating AIS ReMEDy2 interim analysis in 2H 2026.

R&D Spending Expected Rise R&D expenses expected to moderately increase as DM199 program advances into PE and global ReMEDy2 expansion.

ATM Offering Available $98.4M remains available under the August 2025 At-The-Market offering program for future capital needs.

Peer Comparison

Revenue (TTM)

HUMA

$8.80M

+0.0%

KRRO

$7.37M

+0.0%

DBVT

$511.00K

-95.5%

Gross Margin (Latest Quarter)

ALT

57207.7%

-299200.0pp

KRRO

100.0%

+0.0pp

HUMA

65.5%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ANNX	$727.14M	-4.4	-92.3%	11.8%
REPL	$679.57M	-2.4	-102.7%	23.6%
DRTS	$583.21M	-14.3	-56.5%	12.9%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 16, 2026

EPS:-$0.17

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data